# ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

> **NCT00051493** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 50 (—)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** ALIMTA
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00051493
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2002-12
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051493, "ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00051493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*